162 related articles for article (PubMed ID: 10604579)
1. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
2. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Reif S; Aeed H; Shilo Y; Reich R; Kloog Y; Kweon YO; Bruck R
J Hepatol; 2004 Aug; 41(2):235-41. PubMed ID: 15288472
[TBL] [Abstract][Full Text] [Related]
3. Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid.
Oron T; Elad-Sfadia G; Haklai R; Aizman E; Brazowski E; Kloog Y; Reif S
Dig Dis Sci; 2012 Feb; 57(2):320-6. PubMed ID: 21901261
[TBL] [Abstract][Full Text] [Related]
4. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Clarke HC; Kocher HM; Khwaja A; Kloog Y; Cook HT; Hendry BM
J Am Soc Nephrol; 2003 Apr; 14(4):848-54. PubMed ID: 12660318
[TBL] [Abstract][Full Text] [Related]
5. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
Nevo Y; Aga-Mizrachi S; Elmakayes E; Yanay N; Ettinger K; Elbaz M; Brunschwig Z; Dadush O; Elad-Sfadia G; Haklai R; Kloog Y; Chapman J; Reif S
PLoS One; 2011 Mar; 6(3):e18049. PubMed ID: 21445359
[TBL] [Abstract][Full Text] [Related]
6. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.
Neeman R; Abramovitch S; Sharvit E; Elad-Sfadia G; Haklai R; Kloog Y; Reif S
Dig Dis Sci; 2014 Oct; 59(10):2462-9. PubMed ID: 24942325
[TBL] [Abstract][Full Text] [Related]
8. RAS inhibitors: potential for cancer therapeutics.
Kloog Y; Cox AD
Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
[TBL] [Abstract][Full Text] [Related]
9. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells.
Zvibel I; Bar-Zohar D; Kloog Y; Oren R; Reif S
Dig Dis Sci; 2008 Apr; 53(4):1048-53. PubMed ID: 17934818
[TBL] [Abstract][Full Text] [Related]
10. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Biochem Biophys Res Commun; 1997 Oct; 239(3):900-4. PubMed ID: 9367867
[TBL] [Abstract][Full Text] [Related]
11. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
12. Novel Ras antagonist blocks human melanoma growth.
Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
[TBL] [Abstract][Full Text] [Related]
14. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
Karussis D; Abramsky O; Grigoriadis N; Chapman J; Mizrachi-Koll R; Niv H; Kloog Y
J Neuroimmunol; 2001 Nov; 120(1-2):1-9. PubMed ID: 11694313
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats.
Marciano D; Shohami E; Kloog Y; Alexandrovitch A; Brandeis R; Goelman G
J Neurotrauma; 2007 Aug; 24(8):1378-86. PubMed ID: 17711399
[TBL] [Abstract][Full Text] [Related]
16. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
17. Ras inhibitor S-trans, trans-farnesylthiosalicylic acid enhances spatial memory and hippocampal long-term potentiation via up-regulation of NMDA receptor.
Wang Y; Chen T; Yuan Z; Zhang Y; Zhang B; Zhao L; Chen L
Neuropharmacology; 2018 Sep; 139():257-267. PubMed ID: 29578035
[TBL] [Abstract][Full Text] [Related]
18. Dislodgment and accelerated degradation of Ras.
Haklai R; Weisz MG; Elad G; Paz A; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y
Biochemistry; 1998 Feb; 37(5):1306-14. PubMed ID: 9477957
[TBL] [Abstract][Full Text] [Related]
19. A protective effect of pyrrolidine dithiocarbamate in a rat model of liver cirrhosis.
Bruck R; Schey R; Aeed H; Hochman A; Genina O; Pines M
Liver Int; 2004 Apr; 24(2):169-76. PubMed ID: 15078482
[TBL] [Abstract][Full Text] [Related]
20. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
George J; Afek A; Keren P; Herz I; Goldberg I; Haklai R; Kloog Y; Keren G
Circulation; 2002 May; 105(20):2416-22. PubMed ID: 12021230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
